New treatment for cannabis use disorder
Official title: Treatment for cannabis use disorder
Funded at Artiam Bio INC. · NIH-10546566 · Data updated 2026-11-12
This study is working on a new pill to help people who have trouble with cannabis use, aiming to reduce cravings and make it easier to manage without serious side effects.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Artiam Bio INC. NIH-funded |
| Lab location | 1 site (Cary, United States) |
| Project start | August 1, 2022 |
| Project end | July 31, 2025 |
| Funding year | 2022 |
| Award (this year) | $319,898 |
| NIH project number | 1R43DA057168-01 |
| Project ID | NIH-10546566 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with cannabis use disorder who are seeking treatment options.
✕Less likely to help
Patients who do not have cannabis use disorder or those who are not interested in pharmacotherapy may not benefit from this research.
What this research studies
This research aims to develop a new medication for cannabis use disorder (CUD), which affects millions of Americans. The approach involves creating a second-generation partial inverse agonist of the cannabinoid 1 receptor (CB1), designed to reduce cravings and the rewarding effects of cannabis without causing significant adverse effects. The medication is expected to be taken orally and is being developed to have a better safety profile compared to previous treatments. This innovative pharmacotherapy could provide a much-needed solution for individuals struggling with CUD.
Why it matters
Potential benefit: If successful, this research could lead to an effective medication that helps individuals overcome cannabis use disorder.
How similar studies have gone: Previous research has shown that targeting the cannabinoid receptors can be effective in treating substance use disorders, indicating a promising avenue for this new approach.
Where this research is happening
-
Artiam Bio INC.
Cary, United States Active
Researchers
- Principal investigator: Seltzman, Herbert H — Artiam Bio INC.
- Study coordinator: Seltzman, Herbert H
Related research
Other NIH-funded projects on the same topics.
-
Hemp-derived CBD for reducing cannabis use in high-THC concentrate users
A randomized, placebo-controlled trial tests whether hemp-derived CBD can help adults who mainly use high-potency cannabis concentrates reduce their cannabis use.
-
Varenicline for Cannabis Use Disorder in Men and Women
A clinical trial will test if varenicline helps people with cannabis use disorder, with a focus on differences between men and women and added counseling to support craving and mood management.
-
Cannabis Use Disorder and Opioid Health Risks in Veterans: A Long-Term VA Study
A long-term study of veterans looking at how cannabis use disorder and its treatment relate to opioid-related health problems and hospital visits.
-
One-session computerized program with text reminders to help manage distress and reduce cannabis use
A short computer-delivered emotional skills session plus just-in-time text reminders to help people who use cannabis and struggle with handling distress learn to tolerate emotions and cut back on use.
-
Advancing Pregnenolone as a Therapy for Cannabis Use Disorder with Depression
A study tests pregnenolone as a therapy for adults who have both cannabis use disorder and depression and aims to reduce cannabis use and improve mood.
-
Cannabis use and HIV: how pot may affect aging and HIV outcomes
A big study will look at how cannabis use and cannabis use disorder affect older people with HIV, including how it relates to aging problems and HIV treatment success.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.